Business
Regeneron enters radiopharma through $2.1B Telix deal
The companies will co-develop and co-commercialize next-generation radiopharmaceutical therapies, with Telix receiving $40M upfront and eligibility for up to $2.1B in milestones.
Company
Regeneron
Business
Telix, Regeneron enter $2.1B radiopharma partnership
The companies will co-develop radiopharmaceutical therapies and radiodiagnostics across multiple solid tumor targets.